Get started
KAROLINSKA DEVELOPMENT AB SER.BKAROLINSKA DEVELOPMENT AB SER.BKAROLINSKA DEVELOPMENT AB SER.B

KAROLINSKA DEVELOPMENT AB SER.B

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

KDEV fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Karolinska Development AB engages in the investment in pharmaceutical and medical technology companies. Its portfolio investments include Umecrine Cognition, Forendo Pharma, OssDsign, Modus Therapeutics, Dilafor, Aprea Therapeutics, Lipidor, Promimic, and Asarina Pharma. The company was founded in 2003 and is headquartered in Solna, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

KDEV does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company